Medical Device and Diagnostic Industry (MD+DI)

Emboline Achieves Milestone with Emboliner System in Pivotal Trial for Embolic Protection in TAVR Patients

Emboline is one step closer to the commercialization of its Emboliner Embolic Protection System. The Santa Cruz, CA-based ...

Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...
Yahoo Finance

Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk ...

SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as ...
Finanznachrichten

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding Embolic Protection Medical Device

SANTA CRUZ, Calif., Oct. 28, 2024 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company based in Santa Cruz, CA, USA, today announced filing of a patent infringement lawsuit ...
Wall Street Journal

Emboline Gets $10 Million to Make Common Heart Procedure Safer

Investors are funding Emboline Inc.’s bid to make a common heart procedure safer. Replacing heart valves has conventionally been done in open-heart surgery. A newer approach, called TAVR, enables them ...

Emboline, Inc.: Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner Presented as a Late-Breaking Clinical Trial at ACC 2026

PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and regulator ...